FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2013/07/003793 [Registered on: 01/07/2013] Trial Registered Retrospectively
Last Modified On: 22/11/2019
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug 
Study Design  Randomized, Parallel Group, Multiple Arm Trial 
Public Title of Study   Evaluation of safety and efficacy of Controlled release Hydrochlorothiazide in stage I Essential Hypertension 
Scientific Title of Study   Comparative Evaluation of Safety and Efficacy of Hydrochlorothiazide CR with Hydrochlorothiazide and Chlorthalidone in patients with Stage I Essential Hypertension 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
Ipca/HCCT/PIII-10,version no-Nil, version date-Nil  Protocol Number 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Anil Pareek 
Designation  President, Medical Affairs and Clinical Research 
Affiliation  Ipca Laboratories Ltd. 
Address  Ipca Laboratories Ltd, 142AB, Kandivli Industrial Estate, Kandivli(W), Mumbai

Mumbai
MAHARASHTRA
400067
India 
Phone  022-66474641  
Fax  022-28686954  
Email  anil.pareek@ipca.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Anil Pareek 
Designation  President, Medical Affairs and Clinical Research 
Affiliation   
Address  Ipca Laboratories Ltd, 142AB, Kandivli Industrial Estate, Kandivli(W), Mumbai

Mumbai
MAHARASHTRA
400067
India 
Phone  022-66474641  
Fax  022-28686954  
Email  anil.pareek@ipca.com  
 
Details of Contact Person
Public Query
 
Name  Nitin Chandurkar 
Designation  Deputy General Manager 
Affiliation  Ipca Laboratories Ltd. 
Address  Ipca Laboratories Ltd,142AB, Kandivli Industrial Estate, Kandivli(W), Mumbai

Mumbai
MAHARASHTRA
400067
India 
Phone  022-61113165  
Fax  022-61113150  
Email  nitin.chandurkar@ipca.com  
 
Source of Monetary or Material Support  
Ipca Laboratories Ltd. Mumbai 
 
Primary Sponsor  
Name  Ipca Laboratories Ltd Mumbai 
Address  142AB, Kandivli Industrial Estate, Kandivli(W),Mumbai,Maharashtra-400067 
Type of Sponsor  Pharmaceutical industry-Indian 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study
Modification(s)  
No of Sites = 16  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Kamal Sharma  Dr Kamal Sharma Cardiology Clinic   A-406, 4th floor, Shivalik Yash, Pallav cross Road, 132 ft ring road, Naranpura, Ahmedabad, Gujarat-380013
Ahmadabad
GUJARAT 
09426020154

kamalsharma1975@rediffmail.com 
Dr S L Mathur  Dr.S.N.Medical College and MDM Hospital  Gyansar, A-5, Shastri nagar, Dalle khan ki Chakki Square, near Krishna Medical, Pal Road, Jodhpur
Jodhpur
RAJASTHAN 
09214409813

mathur_shyam@yahoo.com 
Dr Arati Lalchandani  GSVM Medical College  GSVM Medical College and Lala Lajpat Rai Hospital, OPD Room No. 8, Swaroop Nagar, Kanpur - 208002
Kanpur Nagar
UTTAR PRADESH 
09839870077

davelalchandani@gmail.com 
Dr Atul Abhyankar  Heart First Cardiac and Vascular Centre   F-10, 3rd Floor, Next to D.Khushaldas jewellers, Sheron Plaza,Opp. Ambika Niketan Bus stop, Athwalines Road, Parle Point, Surat-395007, Gujarat
Surat
GUJARAT 
09824145738
0261-3072879
atulda@hotmail.com 
Dr Rajiv Raina  Indira Gandhi Medical college  OPD 511,2E,B-Block 4th floor,Indira Gandhi Medical College, Shimla- 171001 Himachal Pradesh
Shimla
HIMACHAL PRADESH 
09418452815

rajivrainaigmc@gmail.com 
Dr Jyotirmoy Pal  IPGMER and SSKM Hospital  Institute of Post Graduate Medical Education and Research, And SSKM Hospital, 4th Floor, Ronald Ross Building, 244, A. J. C. Bose Road, Kolkata – 700020
Kolkata
WEST BENGAL 
09433230319

j_pal2004@rediffmail.com 
Dr A G Ravishankar  K R Hospital  Department of Medicine Krishna Rajendra Hospital Opp Mysore Medical College & Research Institute Irwin Road Mysore – 570 001
Mysore
KARNATAKA 
09845671598
08212420142
airodyravishank@yahoo.co.in 
Dr Anil Godbole  KEM Hospital Research Centre, Pune  Department of Medicine, 5th Floor, KEM Hospital, Rasta Peth, Sardar Moodliar Road,Pune, Maharashtra – 411011
Pune
MAHARASHTRA 
09422037431

dranilgodbole@rediffmail.com 
Dr G Vijayaraghavan  Kerala Institute of Medical Science  Kerala Institute of Medical Science, P.B.No.1, Anayara P.O, Trivandrum- 695 029, Kerala, India
Thiruvananthapuram
KERALA 
9847060855

kims.remedy@gmail.com 
Dr B L N Prasad  King George Hospital  Unit-5, Department of Medicine, King George Hospital,Research Room (Medicine Block), Beside Nizams Medicals, Visakhapatnam-530002,A.P
Visakhapatnam
ANDHRA PRADESH 
09848211931

amcmedicine@hotmail.com 
Dr Manish Agarwal  Medilink Hospital Research Centre, Ahmedabad  Medilink Hospital Research Center Near Shyamal Char Rasta, 132 Ft. Ring Road, Satellite, Ahmedabad – 380 015
Ahmadabad
GUJARAT 
9825443397

medilinkresearchcentre@yahoo.com 
Dr S Selvamani  Meenakshi Mission Hospital and Research Centre  Meenakshi Mission Hospital and Research Centre, Lake Area, Melur Road, Madurai, Tamil Nadu- 625 107, India
Madurai
TAMIL NADU 
9842158868

maniselva@hotmail.com 
Dr Mukund Kumbla  Omega Hospital  4th Floor,Mahaveer circle, Kankanady, Mangalore-575002, Karnataka
Dakshina Kannada
KARNATAKA 
09845082811
0824-2432925
drmukund@epsilon.net.in 
Dr P P Kshirsagar  Rajiv Gandhi Medical College and Chatrapati Shivaji Maharaj Hospital  Rajiv Gandhi Medical College and Chatrapati Shivaji Maharaj Hospital, Old Thane Belapur Road, Kalwa, Dist- Thane- 400 605, Maharashtra, India
Thane
MAHARASHTRA 
9867936579

prasitapk@yahoo.co.in 
Dr Sudhir Bhandari  SMS Medical College and attached Hospital, Jaipur  Department of Medicine, SMS Medical College and attached Hospital, Jawaharlal Nehru Marg, Jaipur - 302004
Jaipur
RAJASTHAN 
9829078844

dr.bhandaricr@gmail.com 
Dr Mrinal Kanti Das  The Calcutta Medical Research Institute  The Calcutta Medical Research Institute, 7/2, Diamond Harbour Road, Kolkata -700027, West Bengal, India
Kolkata
WEST BENGAL 
9830034263

drmkdas2001@yahoo.co.in 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 16  
Name of Committee  Approval Status 
Aadhya Independent Ethics Comittee Ahmedabad  Approved 
Ethics Committee, SMS Medical College and Attached Hospitals, Jaipur  Approved 
Heart First Ethics Comittee, Surat  Approved 
Instituional Ethics Committee, Mysore Medical College and Research Institute, Mysore  Approved 
Instituional Ethics Committee,Indira Gandhi Medical College, Shimla  Approved 
Institutional Ethics Committee of The Calcutta Medical Research Institute  Approved 
Institutional Ethics Committee, GSVM Medical College, Kanpur  Submittted/Under Review 
Institutional Ethics Committee, King George Hospital, Visakhapattanam  Approved 
Institutional Ethics Committee,Dr. S. N. Medical College and MDM Hospital, Jodhpur  Approved 
Institutional Human Ethics Committee Kerala Institute of Medical Science  Approved 
IPGME&R Research Oversight Committee  Approved 
KEM Hospital Research Centre, Ethics Commitee, KEM Hospital, Pune  Approved 
Medilink Ethics Committee  Approved 
MMHRC - Institutional Ethics Committee   Approved 
Omega Ethics Comittee, Mangalore  Approved 
The Institutional Clinical Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Approved/Obtained 
 
Health Condition / Problems Studied
Modification(s)  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I10||Essential (primary) hypertension,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Chlorthalidone 6.25mg  Dose-Chlorthalidone-6.25mg, Frequency-OD, Mode of administration- Oral, Duration-84 Days 
Comparator Agent  Conventional Hydrochlorothiazide 12.5 mg  Dose-Conventional Hydrochlorothiazide-12.5 mg, Frequency-OD, Mode of administration- Oral, Duration-84 Days 
Intervention  Hydrochlorothiazide (controlled released)12.5 mg  Dose-Hydrochlorothiazide(controlled released-12.5 mg), Frequency-OD, Mode of administration- Oral, Duration-84 Days 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  65.00 Year(s)
Gender  Both 
Details  i)patients with Systolic Blood Pressure-140-159mmHg and Diastolic Blood Pressure-90-99mmHg 
 
ExclusionCriteria 
Details  i)patients with secondary hypertension
ii) Patients with significant cardiovascular disease
iii)Patients with abnormal renal, liver function
iv)Patients currently uncontrolled on thiazide type diuretics
v)patients who have used another investigational agent/device within last 30 days prior to enrollment
vi) Patients taking concomitant medications known to alter the blood pressure or to affect the action of study drug
vii) Patients with known history of hypersensitivity to study drugs or other drugs of same chemical class
viii) Pregnant or lactating women or women of child-bearing potential not practicing contraception 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Pre-numbered or coded identical Containers 
Blinding/Masking   Double Blind Double Dummy 
Primary Outcome  
Outcome  TimePoints 
To demonstrate comparative efficacy of Hydrochlorothiazide(controlled release)with chlorthalidone 6.25mg and also its superiority to hydrochlorothiazide 12.5mg with respect to change in 24 hr mean systolic and diastolic ambulatory blood pressure from baseline to week 4 and week 12  24 hr ABPM will be meausred at baseline, Week 4, and Week 12.  
 
Secondary Outcome  
Outcome  TimePoints 
i)To compare change in mean office systolic and diastolic blood pressure at each visit from baseline
ii)To compare change in ambulatory daytime and nighttime mean systolic and diastolic blood pressure from baseline to week 4 and week 12
iii)To assess the safety and tolerabilty of test drugs compared to reference product 
i)Office systolic and diastolic blood pressure will be measured at baseline, Day 7, Day 14, Day 28, Day 42, Day 56,Day 70,Day 84
ii)mean day-time and night-time ambulatory measurements at baseline, Week 4 and Week 12.
iii) Safety and tolerability of study medications throughout the study 
 
Target Sample Size   Total Sample Size="213"
Sample Size from India="213" 
Final Enrollment numbers achieved (Total)= "54"
Final Enrollment numbers achieved (India)="54" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   17/12/2012 
Date of Study Completion (India) 12/05/2015 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Date Missing 
Estimated Duration of Trial   Years="1"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Completed 
Publication Details   NA 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Brief Summary  

This is a randomized, comparative, double blind, double dummy, parallel group, multicentric study comparing efficacy and safety of Hydrochlorothiazide CR with Conventional Hydrochlorothiazide and Chlorthalidone in Patients with Stage 1 Essential Hypertension. The primary objective is to demonstrate that Hydrochlorothiazide CR 12.5 mg is as effective as Chlorthalidone 6.25 mg and is superior to Conventional Hydrochlorothiazide 12.5 mg with respect to change in 24-hr mean systolic (SBP) and diastolic (DBP) ambulatory BP from baseline to Week 4 and Week 12.The secondary objective is to compare the change in mean office SBP and DBP at each visit from baseline, to compare the change in ambulatory daytime and nighttime mean SBP and mean DBP from baseline to Week 4 and Week 12 and to assess the safety and tolerability of the test product as compared to the reference product

 

 
Close